Generate QR code
Open Access
Subscription Access
Experience with canakinumab in patients with familial mediterranean fever
https://doi.org/25557/2073-7998.2025.11.100-102
Abstract
Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease, associated with mutations in the MEFV gene, characterized by recurrent febrile attacks, abdominal pain, arthritis, and systemic inflammation. The high risk of amyloidosis necessitates pathogenetic therapy, especially in colchicine-resistant cases. This report presents clinical experience with the use of canakinumab in three children with colchicine-resistant FMF. Two patients, including a 3-year-old girl, showed significant clinical and laboratory improvement after 4 and 12 weeks of therapy. No serious adverse effects were observed during follow-up. The treatment involved subcutaneous injections of 2 mg/kg of canakinumab once every 4 weeks, resulting in remission and reduced systemic inflammation. These findings confirm the safety and efficacy of canakinumab in pediatric patients with severe colchicine-resistant FMF, expanding therapeutic options for this disease.
Keywords
familial Mediterranean fever,
canakinumab,
biological therapy,
colchicine resi stance,
systemic inflammation
Supporting agencies: This research received no external funding
About the Authors
S. Piskunova
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015
E. A. Ligostaeva
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015
M. S. Chernova
Regional Children’s Clinical Hospital; Rostov State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015; 119/80, Suvorova st., Rostov-on-Don, 44022
V. V. Ligostaeva
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015
M. S. Chernova
Regional Children’s Clinical Hospital; Rostov State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015; 119/80, Suvorova st., Rostov-on-Don, 44022
V. Yu. Avdeenko
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015
M. V. Lopukhina
Regional Children’s Clinical Hospital
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015
N. N. Sevryugina
Regional Children’s Clinical Hospital; Rostov State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
14, 339 Strelkovoy Divizii st., Rostov-on-Don, 344015; 119/80, Suvorova st., Rostov-on-Don, 44022
D. A. Shapovalova
Rostov State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
119/80, Suvorova st., Rostov-on-Don, 44022
References
1. Akhmedov V.A., Morova N.A., Bikbavova G.R. Semeynaya sredizemnomorskaya likhoradka: obzor literatury i sluchay iz praktiki [Family Mediterranean fever: literature review and case study]. Meditsinskiy opponent [Medical Opponent]. 2023; 1 (21): 59–64. (In Russ.)
2. Eldad B.C. Old paradigms and new concepts in familial Mediterranean fever (FMF): an update 2023. Rheumatology(Oxford, England). 2024; 63(2): 309–318.
3. Lancieri M., Bustaffa M., Palmeri S. et al. An Update on Familial Mediterranean Fever International journal of molecular sciences. 2023;24(11):9584.
4. Tufan A., Lachmann H.J. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish journal of medical sciences. 2020;50(SI-2):1591-1610.
5. Tomokawa T., Koga T., Endo Y., et al. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study. Mod Rheumatol. 2022;32(4):797-802.
Review
For citations:
Piskunova S., Ligostaeva E.A., Chernova M.S., Ligostaeva V.V., Chernova M.S., Avdeenko V.Yu., Lopukhina M.V., Sevryugina N.N., Shapovalova D.A. Experience with canakinumab in patients with familial mediterranean fever. Medical Genetics. 2025;24(11):100-102. (In Russ.) https://doi.org/25557/2073-7998.2025.11.100-102
Views:
11
Email this article 